Skip to content

the effect of Acetaminophen and Ibuprofen for closure of patent ductus arteriosus (PDA )

Studying the efficacy of synchronous consumption of Acetaminophen and Ibuprofen for closure of patent ductus arteriosus (PDA ) in preterm neonates admitted in neonatal intensive care unit

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20171116037503N2
Enrollment
210
Registered
2018-10-30
Start date
2017-09-23
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patent ductus arteriosus. Patent ductus arteriosus

Interventions

Intervention 1: The first intervention group consists of 70 premature neonate who received an intravenous injection of 15 mg acetaminophen per kg of body weight every 6 hours for three days. Intervent

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Days to 30 Days

Inclusion criteria

Inclusion criteria: premature infants less than 37 weeks of gestational age premature infants who require treatment for patent ductus arteriosus

Exclusion criteria

Exclusion criteria: 1 . Prohibition of oral feeding 2.massive bleeding from ETT or GI bleeding 3. Platelet count less than 50/000 per mili cubic meter 4. Urine output less than 1mililitr per kilogram per hour 5. Serum creatinine greater than 1.5miligram per decilitre 6. Intra-ventricular hemorrhage grade 3 and 4 7. Increase more than 2 times the hepatic enzymes (NL ALT: 6-50 and NL AST: 35-140) 8-Major Congenital Anomalies 9-Congenital Heart Disease 10-Sepsis 11-Persistent Fetal Circulation

Design outcomes

Primary

MeasureTime frame
Closing patent ductus arteriosus. Timepoint: before intervention and on day four after end of treatment. Method of measurement: Ecocardiography.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRoya Oboodi

Shiraz University of Medical Sciences

oboodir@sums.ac.ir+98 71 3647 4298

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026